Product Images Flolipid

FloLipid Simvastatin 20mg/5mL Oral Suspension is a medication available in a 150 mL bottle, NDC 2927340104.*

This is a description of FloLipid oral suspension, containing Simvastatin, USP. The inactive ingredients include ethylparaben, magnesium aluminum silicate, methylparaben, propylene glycol, propylparaben, purified water, simethicone emulsion, sodium lauryl sulfate, sodium carboxymethylcellulose sodium, citric acid monohydrate, sodium citrate, diabasic and anhydrous, strawberry flavour. The product comes in a 150 mL container and should be stored at controlled room temperature, 20%-25°C (68°-77°F). The first opening date should be marked and unused portions should be discarded 30 days after. The package insert should be read before use and the drug should be kept out of reach of children.*

Each 5mL of FloLipid oral suspension contains 40 mg of Simvastatin, USP. It is an oral medication used for treating high cholesterol and triglyceride levels. The medication is stored at controlled room temperature, preferably 20°-25°C (68°-77°F) and should not be refrigerated or frozen. It is packed in a tamper-evident container of 150 mL and should be used within 30 days after opening. It contains inactive ingredients like acesulfame potassium, carboxymethylcellulose sodium, citric acid monohydrate, ethylparaben, magnesium aluminum silicate, methylparaben, propylene glycol, propylparaben, purified water, simethicone emulsion, sodium lauryl sulfate, sodium lactate, diabasic, and anhydrous strawberry flavor. Read the package insert before use to get detailed information about the medication. It is manufactured by Rosemont Pharmaceuticals Ltd, Leeds, LS11 9XE, UK, and is made in the United Kingdom.*

The text seems to be a part of a research paper that contains statistical information about a treatment with Simvastatin and its effects on major vascular and coronary events. It includes data on the baseline characteristics of the patients such as age, gender, diabetes, and other diseases. The text also presents the incidence rates and risk ratios of major vascular and coronary events for patients treated with Simvastatin and Placebo.*